Condition: Alzheimer Disease · Sponsor: First Affiliated Hospital of Zhejiang University
The goal of this observational study is to valuate the sensitivity and specificity of different blood biomarkers for monitoring and assessing Aβ-PET-confirmed mitigation of amyloid pathology by lencanumab treatment in subjects treated with lencanumab.
This description comes directly from the study's public registry record.
Guoping Peng, PhD · 13588150613 · pgpfc@163.com
Xiaoyan Liu, PhD · 15824137598 · liuxiaoyandongda@126.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| The First Affiliated Hospital of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07153848